|
Abstract:
|
The HIV Prevention Trial Network (HPTN) 052 Study is a Phase III, controlled, randomized clinical trial to assess the effectiveness of immediate versus delayed antiretroviral therapy strategies on sexual transmission of HIV-1 (Cohen, et al., 2011, New England Journal of Medicine, 365: 493-505). It was hailed by the Science Magazine as the Breakthrough of the Year for 2011 (Alberts, 2011, Science, 334: 1604). In this talk, we will focus on the statistical design and methods that underlie this landmark study in HIV Treatment-as-Prevention, and discuss the lessons that we have learned for future research.
|
